The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
Approval Alert | Nirogacestat in Desmoid Tumors
Patients with desmoid tumors can now receive nirogacestat following the FDA’s approval of the agent.
Advertisement
Advertisement
Trending on CancerNetwork
1
BCMA CAR T-Cell Therapy Improves OS Vs Teclistamab in Multiple Myeloma
2
FDA Grants Priority Review to Giredestrant in ER+/HER2– Early Breast Cancer
3
GLP-1 Receptor Agonists Show Modest Reduction in HR+ Breast Cancer Incidence
4
Decoding RAMPART: Durvalumab Monotherapy Vs Combination Therapy in RCC
5